Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations
← catalyst calendarNCT06160752 · readout ≤ 42 d
Sponsored by Tyra Biosciences, Inc (industry) · TYRA — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
40estimated
Sites
4
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-11-22 | actual | When the study began enrolling |
| Primary completion | Sep 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2023-12-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Locally Advanced Cholangiocarcinoma
- Intrahepatic Cholangiocarcinoma
- Solid Tumor
- Metastatic Cholangiocarcinoma
Interventions
- Drug: Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles
- Drug: Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles
Primary outcomes
what the primary-completion date above is the date OFPhase 1 Part A: To determine the maximum tolerated dose (MTD) of TYRA-200.
measured Initiation of study treatment through 28 Days
Phase 1 Part B: To determine the optimal dose of TYRA-200.
measured Initiation of study treatment through 28 days (up to approximately 18 months
Permalink · TYRA's whole pipeline · Catalyst calendar · Every registered study · What changed